

Manuscript Number: EJPS-D-18-00300R2

Title: P-glycoprotein expression in the gastrointestinal tract of male and female rats is influenced differently by food

Article Type: Research Paper

Keywords: Multidrug resistant protein 1 (mdr1); Sex differences; Meals; Gastrointestinal; Pre-clinical development; Rat models

Corresponding Author: Professor Abdul W Basit,

Corresponding Author's Institution: UCL School of Pharmacy

First Author: Liu Dou



Order of Authors: Liu Dou; Yang Mai; Christine M Madla; Mine Orlu; Abdul W Basit

Manuscript Region of Origin: UNITED KINGDOM

Abstract: The aim of this study was to explore the influence of food on P-gp relative expression in both male and female rats, and its effect on intestinal permeation of P-gp substrates (ranitidine and ganciclovir) and a P-gp non-substrate (metformin). The intestine of 12 male and 12 female Wistar rats were excised and segmented into the duodenum, jejunum, ileum and colon. P-gp extracted from each segment was then determined via Western-blotting. In male rats, the relative P-gp expression decreased significantly after food intake in all segments of the intestine except in the duodenum. The most notable change was demonstrated in the colon where relative expression decreased from 1.75 ± 0.36 in the fasted-state to 0.31 ± 0.15 in the fed-state. In female rats, a fundamentally different result was observed. Food ingestion resulted in a significant increase in relative P-gp expression in all regions of the intestine except in the colon. The largest difference was observed in the jejunum of the fed-state female rat intestine where P-gp expression was 1.76 ± 0.95 which was a six-fold increase from the fasted state at 0.34 ± 0.13. Intestinal permeation studies in an Ussing chamber showed that both ganciclovir and ranitidine exhibited a sex difference in intestinal permeability in the fasted-state. No sex differences and food effects were observed on metformin small intestine permeability. The permeability results of the three drugs highly supported that there was a sex-related food effect on P-gp function in the small intestine. The current study has reported stark differences between male and female rats at a physiological level relating to P-gp expression and the influence of food.

**Abstract**

The aim of this study was to explore the influence of food on P-gp relative expression in both male and female rats, and its effect on intestinal permeation of P-gp substrates (ranitidine and ganciclovir) and a P-gp non-substrate (metformin). The intestine of 12 male and 12 female Wistar rats were excised and segmented into the duodenum, jejunum, ileum and colon. P-gp extracted from each segment was then determined via Western-blotting. In male rats, the relative P-gp expression decreased significantly after food intake in all segments of the intestine except in the duodenum. The most notable change was demonstrated in the colon where relative expression decreased from  $1.75 \pm 0.36$  in the fasted-state to  $0.31 \pm 0.15$  in the fed-state. In female rats, a fundamentally different result was observed. Food ingestion resulted in a significant increase in relative P-gp expression in all regions of the intestine except in the colon. The largest difference was observed in the jejunum of the fed-state female rat intestine where P-gp expression was  $1.76 \pm 0.95$  which was a six-fold increase from the fasted state at  $0.34 \pm 0.13$ . Intestinal permeation studies in an Ussing chamber showed that both ganciclovir and ranitidine exhibited a sex difference in intestinal permeability in the fasted-state. No sex differences and food effects were observed on metformin small intestine permeability. The permeability results of the three drugs highly supported that there was a sex-related food effect on P-gp function in the small intestine. The current study has reported stark differences between male and female rats at a physiological level relating to P-gp expression and the influence of food.



1 **P-glycoprotein expression in the gastrointestinal tract of male and female rats is**  
2 **influenced differently by food**

3 Liu Dou, Yang Mai, Christine M Madla, Mine Orlu, Abdul W Basit\*

4

5 Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29 –  
6 39 Brunswick Square, London, WC1N 1AX, UK

7

8 \*Correspondence: [a.basit@ucl.ac.uk](mailto:a.basit@ucl.ac.uk)

9

10 **Keywords:** Multidrug resistant protein 1 (mdr1); Sex differences; Meals; Gastrointestinal;  
11 Pre-clinical development; Rat models

12

13 **Abstract**

14

15 The aim of this study was to explore the influence of food on P-gp relative expression in both  
16 male and female rats, and its effect on intestinal permeation of P-gp substrates (ranitidine and  
17 ganciclovir) and a P-gp non-substrate (metformin). The intestine of 12 male and 12 female  
18 Wistar rats were excised and segmented into the duodenum, jejunum, ileum and colon. P-gp  
19 extracted from each segment was then determined via Western-blotting. In male rats, the  
20 relative P-gp expression decreased significantly after food intake in all segments of the  
21 intestine except in the duodenum. The most notable change was demonstrated in the colon  
22 where relative expression decreased from  $1.75 \pm 0.36$  in the fasted-state to  $0.31 \pm 0.15$  in the  
23 fed-state. In female rats, a fundamentally different result was observed. Food ingestion  
24 resulted in a significant increase in relative P-gp expression in all regions of the intestine  
25 except in the colon. The largest difference was observed in the jejunum of the fed-state  
26 female rat intestine where P-gp expression was  $1.76 \pm 0.95$  which was a six-fold increase  
27 from the fasted state at  $0.34 \pm 0.13$ . Intestinal permeation studies in an Ussing chamber  
28 showed that both ganciclovir and ranitidine exhibited a sex difference in intestinal  
29 permeability in the fasted-state. No sex differences and food effects were observed on  
30 metformin small intestine permeability. The permeability results of the three drugs highly  
31 supported that there was a sex-related food effect on P-gp function in the small intestine. The  
32 current study has reported stark differences between male and female rats at a physiological  
33 level relating to P-gp expression and the influence of food.

## 34 1.0 Introduction

35

36 It is well-known that males and females respond differently to medicines ([Freire et al., 2011](#);  
37 [Bigos et al., 2009](#); [Nicolas et al., 2009](#)). Despite this, pre-clinical research has demonstrated a  
38 tendency to focus on males in animal studies which may conceal profound sex differences.  
39 To date, no resounding guideline or standardisation practice have been proposed to consider  
40 the variations between male and female animals (Clayton, 2014). In order to advance  
41 pharmaceutical research, it is crucial to establish a better understanding of the innate  
42 differences between the sexes.

43

44 The majority of oral medicines are routinely pre-clinically tested on rats due to its  
45 inexpensiveness, ease of collection and the ability to identify compounds with promising or  
46 toxic biopharmaceutical properties (Downing, 2014). In order to determine the potential  
47 implications of drugs in a sex-dependent manner, it is firstly important to elucidate the  
48 differences in gastrointestinal (GI) physiology between male and female rats. In particular the  
49 efflux transporter intestinal P-glycoprotein (P-gp) is a putative limiting factor the absorption  
50 of drugs (Sharom, 2011; [Lin et al., 2003](#); [Murakami et al., 2008](#); [Zakeri-Milani et al., 2014](#)).  
51 A recent document issued by the Food and Drug Administration (FDA) suggested that the  
52 pharmaceutical industry should evaluate the effect of P-gp in early drug development (FDA,  
53 2017). However, the expression of P-gp in laboratory rats is poorly understood. In the  
54 literature, contradicting results have been reported regarding the segmental differences in P-  
55 gp expression along the small intestine. Several investigations have demonstrated that P-gp  
56 expression increases in the lower segments of the small intestine in rats (Hatton et al., 2015,  
57 [Afonso-Pereira et al., 2018](#); [Mai et al., 2018](#)) although others have reported that the highest  
58 expression can be determined towards the more proximal regions (Makhey et al., 1998,  
59 Yumoto et al., 1999, Stephens et al., 2002, Ho et al., 2003, Berggren et al., 2007). Assessing  
60 the methodologies used to determine P-gp in the literature, however, has revealed disparities  
61 in data collection regarding the reference protein, the strain of rat, the lack of consideration of  
62 potential sex differences and more notably, the influence of food on P-gp expression.

63

64 Food consumption induces dynamic changes in the GI tract (Varum et al., 2013; [Abuhelwa et](#)  
65 [al., 2017](#); [O'Shea et al., 2018](#)) including luminal fluid volume and composition, and patterns  
66 of intestinal motility which ultimately affect the transit time of dosage forms (Ofutet et al.,  
67 [2015](#); [Ibekwe et al., 2008](#); [Fadda et al., 2009](#); [Liu et al., 2009](#)). The understanding of the

68 influence of food on P-gp expression in rodents, its potential difference between sexes and its  
69 implications for oral drug delivery are still in its infancy.

70

71 This study aimed to explore the effect of food on the protein and relative mRNA expression  
72 level of intestinal P-gp. An *ex vivo* study was further conducted to evaluate the intestinal  
73 permeation of P-gp substrates ranitidine and ganciclovir, and a non-P-gp substrate metformin  
74 under the effect of food in both sexes.

75

## 76 **2.0 Materials and Methods**

77

### 78 **2.1 Materials**

79 Ranitidine (a P-gp and organic cation transporter (OCT) protein substrate) and ganciclovir (a  
80 P-gp substrate) were purchased from Sigma Aldrich (Dorset, UK). Metformin hydrochloride  
81 (an OCT protein substrate) was obtained from USV Ltd. (Mumbai, India). NuPAGE LDS  
82 Sample Buffer, Tris Buffered Saline, 10 X Solution, NuPAGE MOPS SDS Running Buffer  
83 (20X), NuPAGE Transfer Buffer (20X) and SuperSignal West Pico Chemiluminescent  
84 Substrate were purchased from Thermo Scientific (Paisley, UK). Tween 20, Bovine Serum  
85 Albumin and Monoclonal Anti- $\beta$ -Actin were obtained from Sigma Aldrich (Dorset, UK).  
86 TBE Running Buffer (5X) and 10X TBE Electrophoresis Buffer were bought from Thermo  
87 Scientific (Paisley, UK). All other chemicals and kits are noted individually in the following  
88 methods.

89

### 90 **2.2 Preparation of intestinal tissues from male and female rats**

91 12 male and 12 female Wistar rats (10 weeks old weighing approximately 250 g and 200 g  
92 respectively) were purchased from Harlan UK Ltd. (Oxfordshire, UK) and housed at room  
93 temperature of 25°C in a light-dark cycle for 12 h. Fed state rats (6 male and 6 female) were  
94 provided with free access to food (EURodent Diet 22%) and water. Fasted state rats (6 male  
95 and 6 female) were subject to an overnight fasting of 12 h prior to the experiment. On the day  
96 of experiment at approximately 8:30 am, rats were sacrificed by a CO<sub>2</sub> euthanasia chamber.  
97 The whole intestinal tract was then rapidly removed and kept in an ice-bath filled with Krebs-  
98 Bicarbonate Ringer's solution (KBR) at pH 7.4. The intestine was then cut into four  
99 segments; the duodenum (1 cm from the ligament of Treitz); jejunum (10 cm from the  
100 ligament of Treitz); ileum (1 cm from the cecum) and colon. Tissue pieces from the mid part  
101 of the duodenum, the proximal part of the jejunum, the distal to mid part of ileum and the

102 descending colon were separated. 1 cm of tissue was used for permeation study and protein  
103 determination, and 2 cm for mRNA determination. The separated tissue was then opened  
104 along the mesenteric border and the mucosal layer was obtained by gently squeezing the  
105 [serosal](#)-side of tissue [with a cover slip on ice-cold glass plate](#). The prepared tissue with the  
106 mucosal layer was then freshly used for the following studies.

107

### 108 ***2.3 Intestinal P-gp protein quantification via Western-blotting***

109 The prepared tissue from section 2.2 was placed into a glass vial containing 3 ml of freshly  
110 prepared lysis buffer (50 mM Tris, 250 mM NaCl, 5 mM EDTA, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM  
111 PMSF, 1% Nonidet P40 and a protease inhibitor cocktail) and homogenised for 20 s at  
112 10,000 rpm with a T18 digital ULTRA-TURRAX<sup>®</sup> (IKA). The homogenised tissue solution  
113 was then incubated in a 4°C fridge for 2 h for protein extraction. Two hours later, the solution  
114 was transferred to a 1.5 ml Eppendorf tube and centrifuged with 10,000 rpm at 4°C for 10  
115 min. The supernatant was transferred to micro-tubes and stored at -20°C until used for  
116 analysis (stable for 6 months). The total extracted protein was quantified according to the  
117 instruction adapted from the Pierce BCA Protein Assay Kit (ThermoFisher, UK).

118

119 25 µg protein sample was suspended in NuPAGE<sup>®</sup> LDS Sample Buffer (Invitrogen,  
120 Carlsbad, CA) and kept in a 70°C incubator for 10 min to induce denaturation. The denatured  
121 protein sample was then loaded on a NuPAGETM NovexTM 4 – 12% Bis-Tris gel  
122 (Invitrogen). 5 µl Sharp Pre-Stained protein standard (Invitrogen) was also loaded as  
123 molecular weight marker. Gel electrophoresis was then applied according to the instructions  
124 from the manufacturer. The separated protein samples in the gel were then transferred to a  
125 nitrocellulose membrane with an XCell SureLock<sup>™</sup> Mini-Cell Electrophoresis System  
126 (Invitrogen). Membranes were blocked with 3% bovine serum albumin (BSA) in tris-  
127 buffered saline with tween (TBS-T) and incubated for 1 h at room temperature (25°C). For  
128 the detection of P-gp and reference protein (β-actin) blots were incubated for 1 h at room  
129 temperature with the respective primary antibodies, diluted in a 3% bovine serum albumin  
130 (BSA) in TBS-T: mouse monoclonal anti-P-gp (C-219 3:200; Enzo Life Science, Exeter,  
131 UK) and anti-β-actin mouse monoclonal antibody (1:2000; Sigma-Aldrich, Poole, UK). The  
132 detection of bound antibodies was completed with affinity-purified rabbit anti-mouse  
133 immunoglobulin G (IgG) coupled to peroxidase (secondary antibody; Sigma) and diluted to  
134 1:5000 in 3% BSA in TBS-T. After 1 h incubation with the secondary antibody conjugated  
135 with horseradish peroxidase, [P-gp and β-actin](#) protein bands were visualised by a chem-

136 luminescence detection method with Pierce™ ECL Western Blotting Substrate  
137 (ThermoFisher). The blots were then photographed with a ChemiDoc XRS camera (Bio-  
138 Rad). The relative expression of P-gp was calculated using the Image Lab™ software linked  
139 to the camera (Bio-Rad).

140

#### 141 ***2.4 Intestinal P-gp mRNA quantification via Reverse-Transcription Polymerase Chain*** 142 ***Reaction***

143 The prepared tissues from section 2.2 were kept in an RNAlater buffer (Thermo Scientific).  
144 The total mRNA from the tissues were then extracted following the instruction from Pure  
145 Link RNA Mini Kit and On-column PureLink® DNase Treatment protocol. The extracted  
146 mRNA samples were stored in a -80°C freezer until analysis. The purification and  
147 quantification of the extracted mRNA was evaluated prior to experiment. The frozen mRNA  
148 samples were firstly thawed on ice and 2 µl mRNA solution was then transferred to a  
149 NanoDrop 2000c Spectrophotometer (Thermo Scientific) for the evaluation.

150

151 Two-step real time PCR was applied for mRNA quantification. The first step was the  
152 preparation of cDNA. 1 µg of extracted mRNA from each sample was reverse transcribed to  
153 cDNA by following the instruction from iScript™ cDNA Synthesis Kit (Bio-Rad). The  
154 second step was Real Time-qPCR (RT-qPCR). A 7500 Real Time PCR System  
155 (ThermoFisher) was applied and the method was adapted from the user guide of SYBR®  
156 Green PCR Master Mix and SYBR® Green RT-PCR Reagents Kit. The experiment was  
157 conducted in a microAmp optical 96-well reaction plate with each well containing a 50 µl  
158 reaction system. This included a 1 ng transcribed cDNA, 25 µl SYBR Mix solution, 5 µl  
159 forward primer, 5 µl reverse primer and 10 µl RNase-free water. The sequences of the  
160 primers were shown in Table 1. The relative quantification of mRNA, *mdr1a*, *mdr1b* and β-  
161 actin (internal standard) was carried out with the programme as follows; The amplification  
162 program consisted of one pre-incubation cycle at 95°C with a 12 min hold, followed by 40  
163 amplification cycles with denaturation at 95°C with a 15 s hold, an annealing temperature of  
164 60°C with a 10 s hold and an extension at 60°C and a 1 min hold. Amplification was  
165 followed by a melting curve analysis. This ran for one cycle with denaturation at 95°C with a  
166 15 s hold, annealing at 60°C with a 1 min hold and melting at 95°C with a 30 s hold. A  
167 negative control was included for each analysed sample by adding deionised water instead of  
168 primers. The control group which contained deionised water instead of cDNA was also  
169 included in each run. The relative expression of *mdr1a* and *mdr1b* mRNA in different



170 samples were obtained by designing the programme on 7500 Real Time PCR System based  
171 on the principal of previous studies (MacLean et al., 2008). The relative expression of P-gp  
172 mRNA, *mdr1a* and *mdr1b* in fasted-state and fed-state rats were calculated using a 7500  
173 software (version 2.0.6, Thermofisher).

174

## 175 ***2.5 Ex-vivo permeation studies***

### 176 ***2.5.1 Evaluation of drug permeation via Ussing chamber***

177 Drug solutions (3 mM ranitidine, 3 mM metformin and 1.96 mM ganciclovir) were freshly  
178 prepared in a KBR solution and stored in a 37°C incubator for the experiment. Intestinal  
179 tissues from the jejunum and ileum were obtained following section 2.2 and the luminal  
180 content was gently washed with KBR solution. The well-prepared mucosal tissues were then  
181 mounted in the vertical Ussing Chamber (Harvard Apparatus Inc., Holliston, MA, U.S.A) as  
182 flat sheets on a 0.28 cm<sup>2</sup> segment holder with needles for stability purposes. The chambers  
183 were tightly screwed with high spring-tension retaining rings and the entire assembly was  
184 maintained at 37°C with a circulating water bath for a 30 min equilibrium period. Tissue  
185 integrity was evaluated every 30 min during the experiment by measuring tissue  
186 transepithelial electrical resistance (TEER) with an EVOMX meter (World Precision  
187 Instruments Inc., WPI, Hertfordshire, United Kingdom). Any duodenal, jejunal, ileal and  
188 colonic segments that presented a value of TEER lower than 20 Ω•cm<sup>2</sup>, 40 Ω•cm<sup>2</sup>, 50 Ω•cm<sup>2</sup>  
189 and 70 Ω•cm<sup>2</sup> respectively at the beginning of experiment was regarded as poorly viable and  
190 excluded immediately. The tissue was not considered viable whenever TEER values  
191 decreased more than 15% from the value measured at the end of equilibration period.

192

193 The study began with a 20 – 30 min equilibrium period. 5 mL KBR solution was added to  
194 both the apical (mucosal surface) and basolateral (endothelial surface) chambers, gassed with  
195 an O<sub>2</sub>/CO<sub>2</sub> (95%/5%) gas mixture. Following the emptying of the chamber, 5 ml of fresh  
196 KBR solution was added in the basolateral chamber whilst 5 ml of the drug solution was  
197 added in the apical chamber. During the experiment, 100 µL solution from basolateral  
198 chamber was withdrawn every 30 min. The experiment lasted for 2 h and the intestinal  
199 permeation was evaluated by analysing the drug amount in the withdrawn samples (mucosa  
200 to serosa, M – S). An equal volume of fresh KBR solution was replaced immediately.

201

### 202 ***2.5.2 Chromatographic analysis***

203 Chromatographic analysis was performed with a high performance liquid chromatography  
204 (HPLC) system (Agilent Technologies, 1260 Infinity) equipped with a pump (model  
205 G1311C), an auto-sampler (model G1329B) and a diode array UV detector (model G1314B).  
206 The methods were summarised in Table 2. Ranitidine and metformin samples were subjected  
207 to HPLC-UV analysis using previously validated methods (Ashiru et al., 2007, Mai et al.,  
208 2017). The evaluation of ranitidine was achieved by using a 5 µm Luna SCX (Phenomenex,  
209 UK) column and a mobile phase mixture of 20:80 (acetonitrile):(0.1 M sodium acetate pH =  
210 5.0) with a flow rate of 2 mL/min. In the case of metformin, a Luna C18 (250 mm × 4.6 mm  
211 I.D./5 µm) column (Phenomenex, UK) was applied with a flow rate of 1 mL/min. The  
212 ganciclovir samples were quantified by HPLC using a Luna C18 (250 mm × 4.6 mm I.D./5  
213 µm) column (Phenomenex, UK) with a flow rate of 1 mL/min. The mobile phase consisted of  
214 0.5% formic acid water and acetonitrile (95:5, v/v). The UV detector was set at 275 nm. A  
215 linear calibration curve was obtained at concentration ranges of 0.5 – 50 µg/ml.

216

## 217 **2.6 Data analysis**

218 The apparent permeability coefficient ( $P_{app}$ ) was calculated for the evaluation of ranitidine,  
219 ganciclovir and metformin permeation study by using the following equation:

$$P_{app}(\text{cm/s}) = \frac{Q}{C \cdot A \cdot t}$$

220 where  $Q$  (µmol) is the total amount of drug that permeated to the basolateral chamber  
221 throughout the incubation time,  $C$  (µmol/mL) is the initial drug concentration in the apical  
222 chamber,  $A$  (cm<sup>2</sup>) is the diffusion area of the Ussing Chamber and  $t$  (s) is the time of  
223 experiment.

224

## 225 **2.7 Statistical analysis**

226 All results are expressed as mean ± SD (n = 6) and were analysed by one-way ANOVA and  
227 followed by a Tukey post-hoc analysis with a 95% confidence interval using IBM SPSS  
228 Statistics 16 (SPSS Inc., Illinois, USA).

229

## 230 **3.0 Results**

### 231 **3.1 P-gp expression along the intestine in fasted-state and fed-state rats**

232 As shown in Figures 1 and 2, the relative expression pattern of intestinal P-gp demonstrated a  
233 stark difference in both sexes following food intake. In male rats, the relative expression level  
234 of P-gp significantly decreased in the jejunum, ileum and colon following food intake whilst

235 the duodenum segment exhibited no significant change. The largest reduction in P-gp  
236 intestinal expression occurred in the colon where levels decreased by approximately 84%  
237 from  $1.73 \pm 0.36$  to  $0.31 \pm 0.15$  ([Supplementary Table A](#)). Interestingly, in female rats, an  
238 entirely contrasting result was observed. Food intake enhanced P-gp expression level along  
239 the intestinal tract except in the colon which remained unchanged; P-gp expression increased  
240 by approximately 200% after food intake in the duodenum (from  $0.39 \pm 0.18$  to  $1.21 \pm 0.77$ )  
241 and in the ileum (from  $0.32 \pm 0.14$  to  $0.90 \pm 0.37$ ). The largest change was observed in the  
242 jejunum region where P-gp expression in the fed-state was  $1.76 \pm 0.95$  which demonstrated a  
243 6-fold increase over the fasted-state at  $0.34 \pm 0.13$ .

244

245 The unexpected food effect on intestinal P-gp was also demonstrated at an mRNA level as  
246 the results of the real time PCR experiment in the current study supported the same effect  
247 following food intake. As shown in Figure 3, male rats in the fed-state demonstrated a  
248 significant decrease in expression of the *mdr1a* gene along the whole intestine. The *mdr1b*  
249 gene, however, maintained a stable expression compared to that of the fasted-state. In female  
250 rats, both the *mdr1a* and *mdr1b* gene achieved a statistically significant increase along the  
251 intestine following food intake. This was consistent with the increase in P-gp expression in  
252 female rats after food consumption.

253

### 254 **3.2 Intestinal permeation of ranitidine, ganciclovir and metformin**

255 The permeability of ranitidine and ganciclovir exhibited a sex difference in the fasted state of  
256 the rat intestine ([Figure 4 and supplementary table C](#)). Ranitidine  $P_{app}$  in the jejunal and ileal  
257 regions of female rats was higher than males ( $8.24 \pm 1.29 \times 10^{-6}$  cm/s versus  $6.78 \pm 1.24 \times 10^{-6}$   
258 cm/s; and  $9.97 \pm 0.52 \times 10^{-6}$  cm/s versus  $6.67 \pm 0.10 \times 10^{-6}$  cm/s respectively). Similarly, in the  
259 case of ganciclovir, the permeability in the jejunum and ileum of female rats were  $10.11 \pm$   
260  $1.51 \times 10^{-6}$  cm/s and  $7.87 \pm 0.53 \times 10^{-6}$  cm/s which were higher than males at  $7.64 \pm 1.48 \times 10^{-6}$   
261 cm/s and  $5.17 \pm 0.63 \times 10^{-6}$  cm/s respectively. However, no significant sex difference was  
262 identified in the intestinal permeability of metformin as it is a non-P-gp substrate.  
263 Interestingly, in the case of ranitidine permeability from the fasted to fed state in males, a  
264 22.7% and a 27.3% increase was observed in the jejunum and ileum respectively whilst that  
265 of females achieved a 25.8% and a 41.3% decrease. Ganciclovir permeability decreased in  
266 the female rat jejunum (36.2%) and ileum (37.8%) from the fasted-state to fed-state. In male  
267 rats, however, an 83.6% and 97.3% increase was observed in the jejunum and ileum

268 respectively. The permeability of metformin remained consistent in the different sexes in  
269 both fasted and fed states.

270

271

#### 272 **4.0 Discussion**

273 Attempts have previously been made using Western blot analysis to investigate the  
274 distribution of P-gp in the rat intestinal tract, for instance; male Sprague-Dawley rats (Brady,  
275 2002); fasted male Wistar rats (Valenzuela et al., 2004, Johnson et al., 2006, Wada et al.,  
276 2013); fed male and female Han-Wistar rats (MacLean et al., 2008); and fed male and female  
277 Wistar rats (Afonso-Pereira et al., 2018). The results of these studies, however, are  
278 inconsistent and further complicated by the differences in the reference proteins used to  
279 normalise transporter abundance. In this study,  $\beta$ -actin was used as the reference protein to  
280 normalise P-gp in male and female rats. As the same amount of total protein was loaded for  
281 each sample analyzation, the variability of  $\beta$ -actin protein bands intensity therefore can be  
282 used to understand the variability of  $\beta$ -actin protein expression in male and female rats. As  
283 shown in Supplementary Table B, there was no significant difference in the intensity of  
284 colour of  $\beta$ -actin protein bands between male and female rats, which demonstrated that  $\beta$ -  
285 actin was consistently expressed, and therefore the relative P-gp expression data are reliable.  
286 In addition, the agreement between the Western blot data and the PCR as well as Ussing  
287 chamber data further support the consistent characteristic of  $\beta$ -actin as a reference protein in  
288 the Western blot analysis. Moreover, no definitive study has considered the effect of food in  
289 P-gp expression between the sexes. This, however, is the first study to report that general  
290 food consumption itself can affect intestinal P-gp expression to different extents in males and  
291 females.

292

293 The *in vivo* relative expression of P-gp protein following food intake highly correlated to the  
294 *in vitro* relative expression of genes coding for P-gp in male and female rats. In male rats, the  
295 significant decrease of *mdr1a* gene highly correlated to the decrease in protein expression  
296 with food intake when compared to the expression in the fasted state. In female rats, a  
297 significant increase in P-gp expression in all intestinal regions was observed after food intake  
298 which correlates to the increase in *mdr1a* and *mdr1b* gene expression. Unlike in male rats, the  
299 *mdr1b* gene in female rats demonstrated a greater enhancement with food when compared  
300 with the *mdr1a* gene. *Mdr1b* may, therefore, be a more important gene for the production of  
301 P-gp in female rats than that of their male counterparts.

302

303 The results of the *ex vivo* study demonstrated that the change in intestinal P-gp following  
304 food intake in male and female rats significantly influenced the intestinal permeation of P-gp  
305 drug substrates. Ranitidine and metformin share the same OCT protein absorption  
306 mechanism, however, ranitidine is also a P-gp substrate (Konig et al., 2013, Leibach and  
307 Ganapathy, 1996, Muller et al., 2005, Bourdet and Thakker, 2006, Collett et al., 1999, Liang  
308 et al., 1995). As a result, the change of permeability of ranitidine highly correlated with the  
309 change of intestinal P-gp protein and mRNA level factoring in food and sex whilst metformin  
310 remained constant in all conditions. Although ganciclovir and ranitidine share the same P-gp  
311 absorption mechanism, ganciclovir experienced a greater modification in intestinal  
312 permeability following food intake. The fact that ranitidine is also an OCT protein substrate,  
313 therefore, may have contributed towards its lower permeation (Collett et al., 1999, Bourdet  
314 and Thakker, 2006, Muller et al., 2005, Li et al., 2011, Shah et al., 2007).

315

316 The potential reasons for this sex-dependent food effect are multifactorial. Firstly, the food  
317 ingredients themselves may contribute to this observed phenomenon. According to the  
318 manufacturer's document, the food supplied for the rats in the current study (EURodent Diet  
319 22%) contained 32 different ingredients (LabDiet, US). [A study demonstrated that certain dietary components including capsaicin, curcumin, \[6\]-gingerol, and resveratrol was able to inhibit the activity of P-gp in human multidrug-resistant carcinoma KB-C2 cells \(Nabekura et al., 2005\). Moreover, the oral administration of 60 mg/kg curcumin, a common food ingredient, can result in a decrease of intestinal P-gp expression in male rats \(Zhang et al., 2007\).](#) Secondly, physiological changes in the intestinal luminal environment during food  
325 consumption may further contribute to the sex difference. Luminal fluid composition is  
326 normally altered from food consumption by the modification in production of bile salts,  
327 cholecystinin (CCK) and glucagon-like peptide-1 (GLP-1). In addition, food-stimulated  
328 sex hormones may also influence the sex-dependent food effect on intestinal P-gp expression.  
329 A study proved that a diet containing menhaden oil n-3 PUFA increased serum oestradiol  
330 concentration levels from 90 pg/ml to approximately 130 pg/ml in pregnant rats (Davis et al.,  
331 2013). With the distribution of receptors in rodent intestine, sex hormones have been  
332 demonstrated to regulate P-gp expression; [testosterone, the primary sex hormone in males, has been shown to induce an inhibitory effect on P-gp \(Wessler et al., 2013\). Conversely, another study](#) reported that P-gp expression significantly increased after the incubation with

335 progesterone and  $\beta$ -estradiol at the concentration of or greater than 10 nM and 100 nM  
336 respectively (Coles et al., 2009).

337

338 The most interesting phenomenon identified in the current study was the notable increase of  
339 P-gp in the small intestine of female rats in the fed state. It can be suggested that this may  
340 occur due to the innate protection required for successful reproduction. In the fasted-state,  
341 female rats exhibited low levels of P-gp expression. In the fed-state, however, as food  
342 contains multiple components of which some may be harmful, the body can protect itself by  
343 increasing the expression of the efflux transporter as a barrier function to hinder the  
344 absorption of potentially toxic food compounds. This mechanism could be a complex  
345 interplay of the modulation of P-gp expression, enzyme reaction and the defence ability of  
346 epithelial cells which may be further influenced by sex hormones. It was reported that  
347 oestrone and oestradiol both increase intestinal enzyme activity in female rats. By  
348 administering b.i.d. 1 mg/kg oestrone and oestradiol for two days in female rats, the  
349 intestinal CYP-450 enzyme concentration was enhanced from  $0.03 \pm 0.01$  nmol/mg in the  
350 control group to  $0.16 \pm 0.01$  and  $0.09 \pm 0.01$  nmol/mg in the oestrone and oestradiol treated  
351 groups respectively Brady (2002). A study conducted investigated ileum tissues obtained  
352 from both male and female rats that were exposed to harsh conditions (such hypoxia for 40  
353 min and acidosis at pH 6.8) and normal conditions (normoxia at a normal pH of pH 7.3) via  
354 an Ussing chamber experiment. Cytokine and nitric oxide concentration levels in the Ussing  
355 chamber were subsequently measured to evaluate the immune-inflammatory response.  
356 Fluorescein Isothiocyanate-dextran (FITC-dextran, molecular weight of 4,300 Da) was  
357 checked to assess the barrier function of the intestinal lumen. As a result, female intestinal  
358 tissue showed a higher anti-inflammatory response and an enhanced intestinal barrier  
359 function when compared with males. More interestingly, the addition of oestradiol in male  
360 rats relieved the intestinal injury and enhanced their anti-inflammatory ability (Homma et al.,  
361 2005).

362

## 363 **5.0 Conclusion**

364

365 The current study is the first to report that relative intestinal P-gp expression was drastically  
366 affected by food and to different extents in male and female rats. In males, intestinal P-gp  
367 decreased at both protein and mRNA level following food intake, however, an increase in

368 expression was observed in female rats. In addition, P-gp expression in both fasted and fed  
369 conditions exhibited a sex difference in the intestinal permeability of P-gp substrates  
370 ranitidine and ganciclovir. Therefore, the influence of food and sex should be acknowledged  
371 and implemented when using animal models for the early stage development of oral  
372 | pharmaceutical products that are known or identified to be P-gp substrates.

373 **References**

374

375 ABUHELWA, A. Y., D. B. WILLIAMS, R. N. UPTON AND D. J. FOSTER. 2017. Food,  
376 gastrointestinal pH, and models of oral drug absorption. *Eur J Pharm Biopharm*, 112,  
377 234-248.

378 AFONSO-PEREIRA, F., DOU, L., TRENFIELD, S. J., MADLA, C. M., MURDAN, S.,  
379 SOUSA, J., VEIGA, F. & BASIT, A. W. 2018. Sex differences in the gastrointestinal  
380 tract of rats and the implications for oral drug delivery. *European Journal of*  
381 *Pharmaceutical Sciences*, 115, 339-344.

382 ASHIRU, D. A. I., PATEL, R. & BASIT, A. W. 2007. Simple and universal HPLC-UV  
383 method to determine cimetidine, ranitidine, famotidine and nizatidine in urine:  
384 Application to the analysis of ranitidine and its metabolites in human volunteers.  
385 *Journal of Chromatography B*, 860, 235-240.

386 BERGGREN, S., GALL, C., WOLLNITZ, N., EKELUND, M., KARLBOM, U.,  
387 HOOGSTRAATE, J., SCHRENK, D. & LENNERNÄS, H. 2007. Gene and Protein  
388 Expression of P-Glycoprotein, MRP1, MRP2, and CYP3A4 in the Small and Large  
389 Human Intestine. *Molecular Pharmaceutics*, 4, 252-257.

390 BIGOS, K. L., B. G. POLLOCK, B. A. STANKEVICH AND R. R. BIES. 2009. Sex  
391 differences in the pharmacokinetics and pharmacodynamics of antidepressants: an  
392 updated review. *Gend Med*, 6, 522-543.

393 BOURDET, D. L. & THAKKER, D. R. 2006. Saturable absorptive transport of the  
394 hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic  
395 cation uptake system and P-glycoprotein. *Pharm Res*, 23, 1165-77.

396 BRADY, J. M., CHERRINGTON, N. J., HARTLEY, D. P., BUIST, S. C., LI, N. AND  
397 KLAASSEN, C. D. 2002. Tissue Distribution and Chemical Induction of Multiple  
398 Drug Resistance Genes in Rats. *Drug Metab Dispos*, 30, 838 - 844.

399 CLAYTON, J. A. A. C., F. S. 2014. NIH to balance sex in cell and animal studies. *Nature*,  
400 509, 282 - 283.

401 COLES, L. D., LEE, I. J., VOULALAS, P. J. & EDDINGTON, N. D. 2009. Estradiol and  
402 progesterone-mediated regulation of P-gp in P-gp overexpressing cells (NCI-ADR-  
403 RES) and placental cells (JAR). *Mol Pharm*, 6, 1816-25.

404 COLLETT, A., HIGGS, N. B., SIMS, E., ROWLAND, M. & WARHURST, G. 1999.  
405 Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine



406 by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. *J Pharmacol*  
407 *Exp Ther*, 288, 171-8.

408 DAVIS, J., KHAN, G., MARTIN, M. B. & HILAKIVI-CLARKE, L. 2013. Effects of  
409 maternal dietary exposure to cadmium during pregnancy on mammary cancer risk  
410 among female offspring. *J Carcinog*, 12, 11.

411 DOWNING, J. R., ALLISON, J. P. HONJO, T. 2014. NIH to require both sexes in  
412 preclinical studies. *Cancer Discov*, 4, 860.

413 FADDA, H. M., E. L. MCCONNELL, M. D. SHORT AND A. W. BASIT. 2009. Meal-  
414 induced acceleration of tablet transit through the human small intestine. *Pharm Res*,  
415 26, 356-360.

416 FDA. 2017. In Vitro Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies.  
417 Guidance for Industry. [Online]. Maryland: Food and Drug Administration.  
418 Available:  
419 [https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/  
420 Guidances/UCM581965.pdf](https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM581965.pdf) [Accessed 12th December 2017].

421 FREIRE, A. C., A. W. BASIT, R. CHOUDHARY, C. W. PIONG AND H. A. MERCHANT.  
422 2011. Does sex matter? The influence of gender on gastrointestinal physiology and  
423 drug delivery. *Int J Pharm*, 415, 15-28.

424 HATTON, G. B., YADAV, V., BASIT, A. W. & MERCHANT, H. A. 2015. Animal Farm:  
425 Considerations in Animal Gastrointestinal Physiology and Relevance to Drug  
426 Delivery in Humans. *J Pharm Sci*, 104, 2747-76.

427 HO, G. T., MOODIE, F. M. & SATSANGI, J. 2003. Multidrug resistance 1 gene (P-  
428 glycoprotein 170): an important determinant in gastrointestinal disease? *Gut*, 52, 759-  
429 66.

430 HOMMA, H., HOY, E., XU, D. Z., LU, Q., FEINMAN, R. & DEITCH, E. A. 2005. The  
431 female intestine is more resistant than the male intestine to gut injury and  
432 inflammation when subjected to conditions associated with shock states. *Am J*  
433 *Physiol Gastrointest Liver Physiol*, 288, G466-72.

434 IBEKWE, V. C., M. K. KHELA, D. F. EVANS AND A. W. BASIT. 2008. A new concept in  
435 colonic drug targeting: a combined pH-responsive and bacterially-triggered drug  
436 delivery technology. *Aliment Pharmacol Ther*, 28, 911-916.

437 JOHNSON, B. M., ZHANG, P., SCHUETZ, J. D. & BROUWER, K. L. 2006.  
438 Characterization of transport protein expression in multidrug resistance-associated  
439 protein (Mrp) 2-deficient rats. *Drug Metab Dispos*, 34, 556-62.

440 KONIG, J., MULLER, F. & FROMM, M. F. 2013. Transporters and drug-drug interactions:  
441 important determinants of drug disposition and effects. *Pharmacol Rev*, 65, 944-66.

442 LEIBACH, F. H. & GANAPATHY, V. 1996. Peptide transporters in the intestine and the  
443 kidney. *Annu Rev Nutr*, 16, 99-119.

444 LI, M., SI, L., PAN, H., RABBA, A. K., YAN, F., QIU, J. & LI, G. 2011. Excipients enhance  
445 intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut  
446 sac and in situ by improved intestinal perfusion. *Int J Pharm*, 403, 37-45.

447 LIANG, R., FEI, Y. J., PRASAD, P. D., RAMAMOORTHY, S., HAN, H., YANG-FENG, T.  
448 L., HEDIGER, M. A., GANAPATHY, V. & LEIBACH, F. H. 1995. Human intestinal  
449 H<sup>+</sup>/peptide cotransporter. Cloning, functional expression, and chromosomal  
450 localization. *J Biol Chem*, 270, 6456-63.

451 LIN, J. H. AND M. YAMAZAKI. 2003. Clinical relevance of P-glycoprotein in drug  
452 therapy. *Drug Metab Rev*, 35, 417-454.

453 LIU, F., R. LIZIO, C. MEIER, H. U. PETEREIT, P. BLAKEY AND A. W. BASIT. 2009. A  
454 novel concept in enteric coating: a double-coating system providing rapid drug release  
455 in the proximal small intestine. *J Control Release*, 133, 119-124.

456 MACLEAN, C., MOENNING, U., REICHEL, A. & FRICKER, G. 2008. Closing the gaps: a  
457 full scan of the intestinal expression of p-glycoprotein, breast cancer resistance  
458 protein, and multidrug resistance-associated protein 2 in male and female rats. *Drug*  
459 *Metab Dispos*, 36, 1249-54.

460 MAI, Y., AFONSO-PEREIRA, F., MURDAN, S. & BASIT, A. W. 2017. Excipient-  
461 mediated alteration in drug bioavailability in the rat depends on the sex of the animal.  
462 *European Journal of Pharmaceutical Sciences*, 107, 249-255.

463 MAI, Y., L. DOU, S. MURDAN AND A. W. BASIT. 2018. An animal's sex influences the  
464 effects of the excipient PEG 400 on the intestinal P-gp protein and mRNA levels,  
465 which has implications for oral drug absorption. *European Journal of Pharmaceutical*  
466 *Sciences*, 120, 53-60.

467 MAKHEY, V. D., GUO, A., NORRIS, D. A., HU, P., YAN, J. & SINKO, P. J. 1998.  
468 Characterization of the regional intestinal kinetics of drug efflux in rat and human  
469 intestine and in Caco-2 cells. *Pharm Res*, 15, 1160-7.

470 MULLER, J., LIPS, K. S., METZNER, L., NEUBERT, R. H., KOEPSSELL, H. &  
471 BRANDSCH, M. 2005. Drug specificity and intestinal membrane localization of  
472 human organic cation transporters (OCT). *Biochem Pharmacol*, 70, 1851-60.

473 MURAKAMI, T. AND M. TAKANO. 2008. Intestinal efflux transporters and drug  
474 absorption. *Expert Opin Drug Metab Toxicol*, 4, 923-939.

475 NABEKURA, T., S. KAMIYAMA AND S. KITAGAWA. 2005. Effects of dietary  
476 chemopreventive phytochemicals on P-glycoprotein function. *Biochem Biophys Res*  
477 *Commun*, 327, 866-870.

478 NICOLAS, J. M., P. ESPIE AND M. MOLIMARD. 2009. Gender and interindividual  
479 variability in pharmacokinetics. *Drug Metab Rev*, 41, 408-421.

480 OFUTET, E. O., OBEMBE, A. O., OKON, V. E. & AYITU, R. A. 2015. Effect of Fasting on  
481 Intestinal Motility and Transit in Albino Wistar Rats. *Trends in Medical Research*, 10,  
482 63-68.

483 O'SHEA, J. P., R. HOLM, C. M. O'DRISCOLL AND B. T. GRIFFIN. 2018. Food for  
484 thought: formulating away the food effect - a PEARL review. *J Pharm Pharmacol*.

485 SHAH, P., JOGANI, V., MISHRA, P., MISHRA, A. K., BAGCHI, T. & MISRA, A. 2007.  
486 Modulation of ganciclovir intestinal absorption in presence of absorption enhancers. *J*  
487 *Pharm Sci*, 96, 2710-22.

488 SHAROM, F. J. 2011. The P-glycoprotein multidrug transporter. *Essays in Biochemistry*, 50,  
489 161 - 178.

490 STEPHENS, R. H., TANIANIS-HUGHES, J., HIGGS, N. B., HUMPHREY, M. &  
491 WARHURST, G. 2002. Region-dependent modulation of intestinal permeability by  
492 drug efflux transporters: in vitro studies in *mdr1a(-/-)* mouse intestine. *J Pharmacol*  
493 *Exp Ther*, 303, 1095-101.

494 VALENZUELA, B., NACHER, A., RUIZ-CARRETERO, P., MARTIN-VILLODRE, A.,  
495 LOPEZ-CARBALLO, G. & BARETTINO, D. 2004. Profile of P-glycoprotein  
496 distribution in the rat and its possible influence on the salbutamol intestinal absorption  
497 process. *J Pharm Sci*, 93, 1641-8.

498 VARUM, F. J., HATTON, G. B. & BASIT, A. W. 2013. Food, physiology and drug delivery.  
499 *Int J Pharm*, 457, 446-60.

500 WADA, S., KANO, T., MITA, S., IDOTA, Y., MORIMOTO, K., YAMASHITA, F. &  
501 OGIHARA, T. 2013. The Role of Inter-segmental Differences in P-glycoprotein  
502 Expression and Activity along the Rat Small Intestine in Causing the Double-peak  
503 Phenomenon of Substrate Plasma Concentration. *Drug Metabolism and*  
504 *Pharmacokinetics*, 28, 98-103.

505 WESSLER, J. D., L. T. GRIP, J. MENDELL AND R. P. GIUGLIANO. 2013. The P-  
506 Glycoprotein Transport System and Cardiovascular Drugs. *Journal of the American*  
507 *College of Cardiology*, 61, 2495-2502.

508 YUMOTO, R., MURAKAMI, T., NAKAMOTO, Y., HASEGAWA, R., NAGAI, J. &  
509 TAKANO, M. 1999. Transport of rhodamine 123, a P-glycoprotein substrate, across  
510 rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-  
511 related compounds. *J Pharmacol Exp Ther*, 289, 149-55.

512 ZAKERI-MILANI, P. AND H. VALIZADEH. 2014. Intestinal transporters: enhanced  
513 absorption through P-glycoprotein-related drug interactions. *Expert Opin Drug Metab*  
514 *Toxicol*, 10, 859-871.


515 ZHANG, W., T. M. TAN AND L. Y. LIM 2007. Impact of curcumin-induced changes in P-  
516 glycoprotein and CYP3A expression on the pharmacokinetics of peroral celirolol  
517 and midazolam in rats. *Drug Metab Dispos*, 35, 110-115.

518

519

Figure 1


[Click here to download high resolution image](#)



**Figure 1.** Relative intestinal P-gp protein expression in fasted-state vs. fed-state rats in A) males and B) females (n = 6).

**Figure 2**


[Click here to download high resolution image](#)




**Figure 2.** Western-blotting results of intestinal P-gp expression in fasted vs. fed conditions in male and female rats.

**Figure 3**  
[Click here to download high resolution image](#)

**A) Male**




**B) Female**



**Figure 3.** Relative expression of intestinal P-gp mRNA *mdr1a* and *mdr1b* gene in the fasted or fed state of A) male and B) female rats (n = 6).

Figure 4

[Click here to download high resolution image](#)



**Figure 4.** Permeation of ranitidine, ganciclovir and metformin in the jejunal and ileal regions of fasted vs. fed state male and female rats (n = 6).



**Table 1.** Sequences of designed primers used in the real-time qPCR experiment

<b>Primers</b>	<b>Sense and Antisense</b>	<b>PCR product (<i>bq</i>)</b>	<b>Reference</b>
<i>mdr1a</i>	Forward 5'-CACCATCCAGAACGCAGACT-3'	159	This paper
	Reverse 5'-ACATCTCGCATGGTCACAGTT-3'		
<i>mdr1b</i>	Forward 5'-AACGCAGACTTGATCGTGGT-3'	144	This paper
	Reverse 5'-AGCACCTCAAATACTCCCAGC-3'		
$\beta$ -actin	Forward 5'-GCAGGAGTACGATGAGTCCG-3'	74	This paper
	Reverse 5'-ACGCAGCTCAGTAACAGTCC-3'		

**Table 2.** Summary of the HPLC methods for ranitidine, ganciclovir and metformin quantification

Drug	Column	Temperature (°C)	Mobile phase	Flow rate (ml/min)	UV detection wavelength (nm)	Injection (µl)	Reference
Ranitidine	SCX (250 mm × 4.6 mm I.D./5 µm)	50	0.1 M Sodium Acetate Buffer (pH 5.0, 80%); Acetonitrile (20%)	2	320	40	Ashiru et al., 2007
Ganciclovir	C18 (250 mm × 4.6 mm I.D./5 µm)	40	0.5% Formic acid water (95%); Acetonitrile (5%)	1	275	20	This paper
Metformin	C18 (250 mm × 4.6 mm I.D./5 µm)	25	10 mM Sodium Dihydrogen Phosphate Buffer with 10 mM Sodium Dodecyl Sulfonate (pH 7.0, 60%); Acetonitrile (40%)	1	234	50	Mai et al., 2017

**Supplementary Material A**

[Click here to download Supplementary Material: Supp Table A.docx](#)

**Supplementary Material B**

[Click here to download Supplementary Material: Supp Table B.docx](#)

**Supplementary Material C**

[Click here to download Supplementary Material: Supp Table C.docx](#)